Ozempic maker Novo Nordisk is building a new $4 billion facility in the U.S. amid weight loss drug shortagesByMiranda NeubauerUpdatedJune 25, 2024
Wegovy helped women lose more weight than men with the same heart condition, study saysByBruce GilPublishedJune 24, 2024
An Ozempic alternative helps people lose weight without as many side effects, study saysByBruce GilUpdatedJune 21, 2024
Gilead says its HIV prevention shot was 100% effective in a clinical trialByBruce GilUpdatedJune 20, 2024
Eli Lilly is cracking down on knock-off versions of its popular weight loss drug ZepboundByBruce GilUpdatedJune 20, 2024
Eli Lilly wants to replace Zepbound with an even stronger weight loss drugByBruce GilPublishedJune 14, 2024
JPMorgan's Ozempic bet, J&J's baby powder settlement, Moderna's COVID-flu vax: Pharma news round upByBruce GilPublishedJune 14, 2024
Now playing Novo Nordisk could surpass LEGO as Denmark’s most valuable brand very soonPublishedJune 12, 2024
Johnson & Johnson will pay $700 million to settle talc baby powder caseByBruce GilPublishedJune 12, 2024
Now playing Ozempic maker Novo Nordisk could soon top even Lego as Denmark's biggest brandByBruce GilPublishedJune 12, 2024
This startup helps Americans get Ozempic and Adderall by using overseas freelancersByBruce GilUpdatedJune 11, 2024
Moderna's COVID-flu combo shot outperformed existing vaccines in a late-stage trialByBruce GilUpdatedJune 10, 2024
Ozempic competitors, psychedelic stocks, and Moderna after COVID: Pharma news roundupByBruce GilPublishedJune 7, 2024
Psychedelic stocks tanked after MDMA-assisted therapy for PTSD had a setbackByBruce GilUpdatedJune 5, 2024
Promising trial data for Moderna-Merck skin cancer vaccine sends stock risingByBruce GilPublishedJune 3, 2024
The race for a weight loss pill heats up as a Novo Nordisk competitor releases new trial resultsByBruce GilUpdatedJune 3, 2024
The FDA may approve psychedelics for treating PTSD. Here's what to knowByBruce GilPublishedJune 3, 2024
